If Dharmanol beta testers describe themselves as "feeling

New Post Public Reply Private Reply Replies (1) Message Board
bellsandwhistles
If Dharmanol beta testers describe themselves as "feeling surprisingly well and healthy" along with feelings of relaxed well-being; banished anxiety; no drowsiness; enhanced activity function; normal pulse, hearing and vision; mental acuity; no psycho-actvity; and quelling of urge to smoke cannabis, how much is the brand worth? This might give some idea. It's a bit dated but tells the story well enough.

Tranquillizers — Sleeping Pills — Anti-Depressants
1

Worldwide sales of prescription drugs exceed $300 billion yearly with tranquillizers, sleeping pills, anti-depressants and other Central Nervous System drugs accounting for an estimated $76 billion in sales.

2

Inappropriate prescribing and uninformed use of prescriptions cost healthcare systems billions of dollars worldwide yearly.

3

Prescription Drugs are the fastest growing sector of worldwide health care costs with health care costs continuing to be the largest component of most governments budgets.

4

Prescription Drugs are fast exceeding the cost of physician services.

5

Benzodiazepines have often been called the most widely prescribed group of drugs in the world and the biggest selling drugs in the history of medicine with worldwide sales in excess of $21 billion in 1999.

6

Approximately 10% – 20% of the world population use tranquilizers and sleeping pills with up to 30% of people over the age of 60 years using these drugs (often over many years having been prescribed them at a much earlier age) and who have become "accidental or involuntary addicts."

7

By law, when a physician prescribes drugs for a patient, the physician is required to ensure that the patient is fully informed of the drugs risks and benefits and consents to the drug therapy with full informed knowledge. Statistics show that this occurs in less than 20% of the patient population.

8

An estimated 4 million people in the United States have used prescribed benzodiazepine tranquillizers and hypnotics (sleeping pills) regularly for 5 – 10 years or more according to a US study in the early 1990s. Similar figures apply in the UK, Europe and in some Asian countries with the trend continuing.

9

The World Health Organization (WHO) estimates that 33% of diseases today are caused by medical treatment i.e. iatrogenic or doctor induced illness. Doctors are the third leading cause of death in the US after heart disease and cancer causing an estimated 250,000 deaths each year according to an article published in the Journal of the American Medical Association, July 2000.

10

An estimated 60% of users of tranquilizers and sleeping pills suffer a mixture of adverse effects and withdrawal after 2 – 4 weeks of use (including therapeutic dose levels) due to tolerance and addiction.

11

Addiction to prescription drugs such as tranquillizers and sleeping pills is the inability to discontinue the use of the drugs as a direct result of the build up of tolerance and when the original dose has progressively less effect and a higher dose is required over time. Tolerance produces a recognized withdrawal syndrome and can precipitate "mini withdrawals" "or inter dose withdrawals" between pills depending on the "half life" of the drugs. This often leads to doctors prescribing increased dosages and/or prescribing another benzodiazepine and/or cross addictions to other drugs, primarily alcohol, to withstand the withdrawal symptoms.

12

Pharmaceutical companies spend more on marketing and promotion of drugs than on research and development — an estimated $15,000 – $20,000 on every doctor with expenditures of $8.3 billion in the United States in 1998.

13

40% of impaired or dead drivers of motor vehicles show prescription drugs in their systems – predominantly tranquillizers and sleeping pills.

14

The adverse effects of benzodiazepines can include: paradoxical agitation, increased behavioural disinhibition, impaired new learning, decreased short and long-term memory, impaired psycho-motor functioning, (many times leading to accidents and/or falls), rage, the appearance or worsening of anxiety and depression, suicidal ideation, emotional anesthesia, floppy baby syndrome, the potential for permanent cognitive impairment, tolerance and addiction leading to acute and protracted withdrawal. These effects have been known for over 2 decades but little has been done to address the problem or to change doctors prescribing habits.

15

The National Centre on Addiction and Substance Abuse at Columbia University in 2001 found that General Practitioners don't properly assess for addictions and alarmingly, fewer than one third can diagnose addiction to prescription drugs — a problem doctors create.

16

Guidelines for acceptable duration of benzodiazepine use dating back over 2 decades state a maximum of 2 – 4 weeks or for intermittent use only. Most recently, guidelines state 7 – 10 days.

17

The infrastructure — detox, treatment and recovery centres available and doctors knowledgeable to help people withdraw from tranquillizers, sleeping pills and anti-depressants — is minimal, and in many cases non existent.

18

Misdiagnosis, misprescribing and mistreatment of patients who trust their doctors to "do no harm" continue today in the area of tranquilizers, sleeping pills and anti-depressants.

19

The high cost to our socio-economic system with the continued indiscriminate prescribing and uninformed usage of these drugs includes health and safety in the work place, career devastation, family dysfunction, productivity losses, car accidents, falls, floppy baby syndrome (similar to fetal alcohol syndrome), lost years of people's lives, lost lives, costs to the legal and justice system, workers' compensation board claims, life and disability insurance claims, social welfare costs, emergency admissions, physicians' fees, pharmacists' fees, drug costs, detox facilities and increased overall costs for healthcare and other public/private sector services.

20

The elderly receive more than twice the number of prescription for psychotropic drugs as do younger people and can experience drug induced dementia, cognitive impairment and falls after years of use.

21

Non "psychiatric" conditions account for 70% of tranquillizer and sleeping pill prescribing and usage.

22

Cross addictions to other drugs and alcohol occur in 73% of benzodiazepine users — many of whom never used or had problems with alcohol or other drugs previously.

23

43% of emergency room suicide attempts or overdoses involve tranquillizers and sleeping pills.

24

Prescription drug addiction to benzodiazepines is far more gripping and debilitating than addiction to heroin or cocaine. Withdrawal is recognized to be more difficult, more prolonged and can last months or years depending on the years of use, dosage and the concurrent prescribing with other drugs.

25

Withdrawal symptoms from tranquillizers and sleeping pills can include insomnia, panic attacks, agitation, hallucinations, paranoia, depersonalization, derealization, depression, pressure in head, anxiety, loss of appetite, weight loss, visual distortions, flashbacks, lack of concentration, agoraphobia, dizziness, sweating, nausea, nightmares, palpitations, creeping sensation in the skin, increased sensitivity to light, touch and smell, pins and needles, numbness, seizures and sometimes death. A too rapid withdrawal causes major hyper excitability of the brain and central nervous system. A slow taper of weeks and months depending on use is recommended under close, ongoing medical supervision by a knowledgeable doctor and/or addiction specialist.

26

A Canadian report released in May 1999 revealed that in 1997 benzodiazepine prescriptions surpassed all other Phamacare prescriptions for women exceeding cardiac drugs, anti-depressants and estrogen. 67% of prescriptions were issued to women.

27

68% of people prescribed tranquillizers and sleeping pills receive their prescriptions from only one doctor.

28

A 1996 study at Stockholm University in Sweden revealed that 51% of patients dependent on sedative/hypnotic drugs (tranquillizers and sleeping pills) showed signs of acquired intellectual deterioration and impairment (which can be permanent).

29

Substance use and mental illness co exist in an estimated 50% – 70% of patients diagnosed with "alleged psychiatric disorders". The DSM III and DSM IV (psychiatric manuals) document substance induced anxiety disorders, substance induced mood disorders and substance induced depressive disorders caused by benzodiazepine use. These "alleged psychiatric disorders" often disappear once a patient is off all medications and as a result of lifestyle changes including exercise and diet.

30

There is extensive worldwide concurrent prescribing of benzodiazepines with antidepressants to approximately 60% of patients/consumers (often prescribed to counteract the adverse/side effects of one category of drugs with another).

31

Many patients are prescribed several different benzodiazepines and several different anti-depressants at the same time. In some cases, patients are further prescribed neuroleptics and then anti psychotics. It is not unsual to find patients on 3 – 7 different nervous system drugs. This is all part of a market "dollar-driven" healthcare system based on an antiquated "disease model" and dependent on a chemical cocktail of drugs.

32

A booming market also exists for anti-depressants such as Prozac, Paxil, Zoloft, Luvox, Wellbutrin and Effexor with worldwide sales in the billions of dollars. Anti-depressants (often referred to as the follow up to Valium 25 years later) in the United States in 2000 reached $10.4 billion in retail sales up 21% over 1999 and representing a startling five-fold increase since 1993.

33

In the United States in 2000 Prozac sales (Eli Lilly) reached $2.6 billion, Zoloft (Pfizer) reached $1.9 billion, Paxil (Smith Kline Beecham) $1.8 billion, Wellbutrin (Glaxo Smith Kline) $850.9 million and Effexor (Wyeth - Ayerst) $815.8 million.

34

Anti-depressants including Prozac, Paxil, Zoloft, Luvox and Celexa can have significant side effects including drug induced mania leading to suicide, suicidal ideation, violence, criminal acts, disinhibition or out of control behaviour; drug induced severe anxiety, agitation and depressions; drug induced obsessions and compulsions; drug induced akathisia (an internal sensation of agitation or discomfort that drives a person to move about and also to lose impulse control); tolerance and addiction leading to a recognized withdrawal syndrome which can include bouts of overwhelming depression, insomnia, fatigue and life-threatening physical effects, psychosis and violent out bursts.

35

During the past decade and with greater frequency, there has been an alarming increase in murder/suicides, suicides, domestic violence, bizarre mass killings, mother (parents) killing children, road and air rage, school shootings and workplace violence in North America where documented evidence has shown the involvement of Prozac, Paxil, Zoloft, Luvox, SSRI/Anti-depressant drugs and/or other mind altering drugs.

36

Most monographs and drug formularies for anti-depressant drugs state "effectiveness and safety in long term use has not been evaluated". Concern has also been expressed regarding anti-depressant prescribing to young children and adolescents (since these drugs have not been approved for use in children under 18 years of age). One million children in the US were reported taking anti-depressants in 1999 — including mint flavoured Prozac.

37

Safe use of anti-depressants during pregnancy has not been established with drug monographs and drug formularies stating that anti-depressants should not be administered to women of child bearing potential unless in the opinion of the treating physician the expected benefits to the patient markedly out weigh the possible hazards to the child or fetus.

38

Prescription Drugs are big business with high profits. The ongoing creation by major international drug companies of expanded markets and new markets for antidepressants include new "alleged diseases" such as "social anxiety disorder" for which Paxil is being promoted heavily in advertising; Prozac as Serafem to treat "mood imbalances associated with premenstrual syndrome" and since Prozac has gone off patent, the drug manufacturer, Eli Lilly has received approval to market a once-weekly version of the drug (based on its "new coating").

39

The drugging of children with Ritalin, another highly addictive central nervous system stimulant, continues with increasing regularity and controversy with Ritalin use nearing a world record. In the United States, usage of Ritalin increased an estimated 70% between 1990 and 1998. Is it a question of "hook" them young and they are customers for life to addictive prescription drugs including tranquillizers, sleeping pills and anti-depressants?

Sources: International research and statistics compiled over 12 years from various sources


Market Media International Corp.
4507 Cedarcrest Avenue,
North Vancouver, BC
V7R 3R2,
Canada


SK3 Group Inc. (SKTO) Stock Research Links

SKTO Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Empirik.ai's $21M for AI in Infrastructure Revolution

Updated Category News Views 3

AI-Powered Infrastructure Takes the Stage Well, here's a tech gambit going full steam: empirik.ai just hit the digital scene with a $21 million war chest. Fresh out of the stealth shadows, they've got big names like Sequoia Capital, S32, Canapi Ventures, and Alumni Ventures stamping their ticket. What's the fuss? They're rolling out the first AI agent designed to...

Continue Reading
Epson & The Photo Managers Highlight Memories in Sept.

Updated Category News Views 8

A Focus on Memory Preservation I remember a time when you kept memories in photo albums, dusty boxes in basements. Now, folks aim to digitize those moments before they're lost forever. With September here, Epson and The Photo Managers are telling us it's time for action. And hey, the campaign’s got a catchy name, 'One Photo, One Story.' Simple, yet it urges us all to...

Continue Reading
ZPMC Names Two New 38,000 DWT Vessels for Chipolbrok

Updated Category News Views 5

Navigating Uncharted Waters with New Vessels Some days, you see a giant leap in an industry and think, "Well, someone's got ambition." Here, we're talking about ZPMC's gutsy naming ceremony for two spanking new 38,000 DWT multipurpose heavy-lift ships destined for Chipolbrok, happening fresh off the docks in Shanghai. Specifications That Make Waves Imagine a vessel the...

Continue Reading
Ivonescimab Shows Strong Survival in Key Lung Cancer Trial

Updated Category News Views 0

New Frontiers in Lung Cancer Treatment Well, here's a story that rattles the cage in the oncology world. The name of the game is ivonescimab, Akeso’s latest move as they toss their hat into the already crowded yet pivotal lung cancer treatment ring. This isn't just some side hustle—they've got Phase III data pointin' straight north, figuratively casting a shadow over...

Continue Reading
Balázs Nagy's Bold Move: Transforming AI Workforce

Updated Category News Views 0

New Horizons in AI: Balázs Nagy Leads There's always that one name that shakes things up, and today it's Balázs Nagy. The guy's not just playing in the AI sandbox; he's leveling the whole thing up with Project NoéMI. He's the big cheese at TheNewPush LLC, beyond just a job title. Nagy’s diving headfirst into AI workforce development in a world screaming for change....

Continue Reading
Art Ave Spurs Rebirth in Downtown DC: A Template for Revival

Updated Category News Views 0

Turning Streets into Art Galleries No one would have believed a stretch of DC's bureaucratic offices was about to morph into a vibrant destination worthy of major art aficionados. But here we are, tipping our hats to the Golden Triangle Business Improvement District (BID), who just snagged the IDA Downtown Achievement Award of Excellence for their Art Ave project. Not...

Continue Reading
Elbphilharmonie Hamburg: 10th Anniversary Marks Milestone

Updated Category News Views 5

Elbphilharmonie's Impact on Hamburg's Cultural Landscape Here we are, staring down the first decade of the Elbphilharmonie, and boy, if that isn't a testament to sticking your neck out for culture, I don't know what is. Opened back on January 11, 2017, this concert hall started as just another controversial project, folks wagging tongues about costs and ambition. But...

Continue Reading
Codoxo Snags 2026 Award for AI Payment Innovation

Updated Category News Views 1

Revolutionizing Healthcare Payment with AI Ah, healthcare and payments—two things that can make even the most patient folks lose their cool. But here comes Codoxo, shaking up this landscape with its Point Zero Payment Integrity solution, and someone's finally giving them the nod they deserve. For those of us who have been in the game for a while, this announcement is...

Continue Reading
Behavioral Crisis Center Saves Mobile $101M Since 2021

Updated Category News Views 0

AltaPointe Saves Millions While Supporting Community Health Let's dig into this remarkable achievement by the AltaPointe Behavioral Health Crisis Center. Since opening its doors in May 2021, the Mobile, Alabama facility has notched up a mind-boggling $101.5 million in community savings. This isn’t merely about numbers on a ledger—it's about real human impact, better...

Continue Reading
SCO at 25: China's Strategic Push for Regional Growth

Updated Category News Views 7

There's a new beat coming out of Central Asia, and it's resonating all the way from China's boardrooms to the barren landscapes of the Gobi Desert. With the Shanghai Cooperation Organization (SCO) celebrating its 25th anniversary, we're witnessing a pivot from a security-centric setup to a full-blown economic collaboration machine. The Landscape of SCO's Evolution Look,...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Collaboration Between Enthusiast Gaming and Frigo Cheese Heads

Updated Category News Views 116

Enthusiast Gaming Teams Up with Frigo Cheese Heads Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leader in gaming media and entertainment, has announced an exciting new partnership with Frigo Cheese Heads, the widely-loved string cheese brand from Saputo. This collaboration aims to engage fans with various sponsored...

Continue Reading
Bullen Ultrasonics: A Precision Manufacturing Force

Updated Category News Views 24

Precision in Every Detail at Bullen Ultrasonics When you start seeing accolades like the IndustryWeek Best Plants Awards, you know someone's doing something right. Bullen Ultrasonics in Eaton, Ohio, is giving the world a run for its money in advanced manufacturing, having cemented itself as one of six finalists for 2026. This isn't just a gold star for effort; it's...

Continue Reading
Recognizing Top Property Managers: Obligo's 2024 Awards

Updated Category News Views 125

Obligo Unveils Renter's Trust Awards for 2024 In an exciting announcement, Obligo showcases the leaders in property management through its fifth annual Renter's Trust Awards. This initiative highlights the companies that prioritize tenant experiences, ensuring that renting is not just a transaction but an enriching journey. Understanding the Importance of Trust in Rental...

Continue Reading
Unlocking the Secrets of Men's Fat Burners for Weight Loss

Updated Category News Views 323

Revolutionizing Weight Loss: Discovering Effective Men's Fat Burners In recent years, the landscape of dietary supplements has evolved significantly, especially for men seeking assistance in their weight loss journey. Wolfson Brands has launched an impressive new line of fat-burning supplements tailored to meet the unique challenges men face when trying to lose weight....

Continue Reading
Stellaromics Unveils Pyxa Platform for Advanced Cancer Research

Updated Category News Views 263

Stellaromics Launches Pyxa Platform in Europe Stellaromics, a trailblazer in the field of 3D spatial biology, has announced the deployment of its innovative Pyxa platform in Europe. This development underscores the company's commitment to advancing oncology research through groundbreaking technologies. Dr. Nigel Jamieson and his team from the University of Glasgow are the...

Continue Reading